Prophase labs announces preliminary positive results for dietary supplement equivir

Commercialization of equivir anticipated after second trial is completed in q2, 2024 garden city, ny, feb. 14, 2024 (globe newswire) -- prophase labs, inc. (nasdaq: prph), a next generation biotech, genomics and diagnostics company, today announced positive preliminary results from its equivir dietary supplement comprehensive trial. preliminary results indicate that this innovative otc dietary supplement has the potential to support and maintain immunity, which – if confirmed at the end of the clinical trial program – may help reduce both the frequency and severity of upper respiratory illnesses including the common cold, flu, and covid-19.
PRPH Ratings Summary
PRPH Quant Ranking